Grant of Options

Cambridge Nutritional Sciences PLC
05 August 2024
 

 

05 August 2024

CAMBRIDGE NUTRITIONAL SCIENCES PLC

("CNSL" or the "Company")

Grant of Options

CNSL, (AIM:CNSL) the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that on 05 August 2024 the Board granted share options (the "Options") over its ordinary shares of 4.0 pence each ("Ordinary Shares") to James Cooper, Chief Operating Officer and Executive Director.

Following this grant of Options, the Company has options in issue over 20,184,049 Ordinary Shares, representing approximately 8% per cent. of the Company's total issued share capital.

Director

Number of Options granted on
 05 August 2024

Exercise Price

Total options held
post issue


James Cooper

2,000,000

4.0p

2,000,000

 

Grant of Options

The Company has granted the Options to incentivise executive director performance for the benefit of all Shareholders.

The Options are subject to time conditions (as set out below); good/bad leaver provisions; and being a director of the Company on the date of vesting.

 

Vesting criteria for Options are subject to time conditions as follows:

Amount Vesting

Time Condition

34 per cent. ("Tranche One")

On the first anniversary of 5 August 2024

33 per cent. ("Tranche Two")

On the second anniversary of 5 August 2024

33 per cent. ("Tranche Three")

On the third anniversary of 5 August 2024

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

For further information, please contact:

Cambridge Nutritional Sciences Plc

Jag Grewal, Chief Executive Officer

 

www.cnsplc.com

investors@cnsplc.com

Cavendish Capital Markets Limited

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

Tel: 020 7220 0500

 

About Cambridge Nutritional Sciences Plc

Cambridge Nutritional Sciences Plc (AIM: CNSL) is the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

James Cooper

2.

Reason for the notification

a)

Position/status

Chief Operating Officer, Executive Director

b)

Initial notification/
Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Nutritional Sciences plc

b)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the
financial instrument

Options over Ordinary Shares of 4.0p each

Identification code

ISIN: GB00B1VCP282

b)

Nature of
the transaction

Grant of Options 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

4.0p

2,000,000

d)

Aggregated information

- Aggregated volume

- Price

 n/a

e)

Date of the
transactions

5 August 2024

f)

Place of the transactions

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings